XSTO
BONEX
Market cap1.46bUSD
Oct 09, Last price
237.20SEK
1D
3.04%
1Q
-0.59%
IPO
688.04%
Name
Bonesupport Holding AB
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bonesupport Holding AB (publ) is an orthobiologics company that specializes in the development and commercialization of injectable bioceramic bone graft substitutes. These products are utilized for treating bone voids and are available internationally, including in Europe and North America. Among its key offerings are CERAMENT Bone Void Filler, a synthetic, injectable, moldable, and drillable solution comprising hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol. Additionally, the company provides CERAMENT G, an injectable ceramic bone graft substitute infused with gentamicin, and CERAMENT V, a synthetic bone void filler containing vancomycin. Bonesupport is also advancing preclinical product candidates focused on promoting bone regrowth. These future solutions are being developed for applications such as trauma, revision arthroplasty, chronic osteomyelitis, oncology, and bone and foot infections related to diabetes. Founded in 1999, the company maintains its headquarters in Lund, Sweden.
Key people
Torbjoern Skoeld
Chief Executive Officer · since 2025
Hakan Johansson
Chief Financial Officer · since 2022
Michael Diefenbeck
Executive Vice President - Medical and Clinical Affairs, Chief Medical Officer · since 2021
Michael Mortensen
Executive Vice President - Research and Development, Operations · since 2024
Michael Roth
General Manager, Executive Vice President - Commercial Operations North America · since 2024
Anna Stegmark
Executive Vice President - Quality Management & Regulatory Affairs · since 2024
Annelie Vikner
Executive Vice President - Global Marketing · since 2019
Fergus Macleod
General Manager, Executive Vice President - Commercial Operations EUROW · since 2019
Helena Brandt
Executive Vice President of Human Resources · since 2024
Director · since 2010
Director · since 2025
Lennart Johansson
Independent Chairman of the Board · since 2019
Mary O'Connor
Independent Director · since 2022
Independent Director · since 2022
Headquarters & legal address
Scheelevägen 19 A
Lund, M 223 70
SE
Lund, M 223 70
SE
Address
Scheelevagen 19 A
Lund, M 223 70
SE
Lund, M 223 70
SE
Previous name
Goldcup 5429 AB
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||